Abstract
Management of hypertension has evolved steadily through 25 years of major clinical trials results modifying both the definition of hypertension and clinical management strategies. Trials experience in heart failure is much less extensive given the far smaller therapeutic market and traditionally often followed on the establishment of an agent or class of therapy in hypertension. Separate product profile development in heart failure is rare. Large outcome trials in heart failure are markedly smaller than those in hypertension and have tended to be confined to the last 15 years or so. There are clear examples of agents developed and successful in clinical use in both conditions but more recently the divergence of trials results in the two conditions has shown that comparable efficacy is no longer something which can be taken for granted. This review considers the past successes and more recent contrasts which have emerged in these traditional areas of pharmacological development.
Keywords: hypertension, heart failure, case linkage, neurohormonal suppression, arterial pressure, risk/benefit ratio
Current Pharmaceutical Design
Title: Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Volume: 9 Issue: 21
Author(s): Robert J. MacFadyen, Gregory Y.H. Lip and Russell Davis
Affiliation:
Keywords: hypertension, heart failure, case linkage, neurohormonal suppression, arterial pressure, risk/benefit ratio
Abstract: Management of hypertension has evolved steadily through 25 years of major clinical trials results modifying both the definition of hypertension and clinical management strategies. Trials experience in heart failure is much less extensive given the far smaller therapeutic market and traditionally often followed on the establishment of an agent or class of therapy in hypertension. Separate product profile development in heart failure is rare. Large outcome trials in heart failure are markedly smaller than those in hypertension and have tended to be confined to the last 15 years or so. There are clear examples of agents developed and successful in clinical use in both conditions but more recently the divergence of trials results in the two conditions has shown that comparable efficacy is no longer something which can be taken for granted. This review considers the past successes and more recent contrasts which have emerged in these traditional areas of pharmacological development.
Export Options
About this article
Cite this article as:
MacFadyen J. Robert, Lip Y.H. Gregory and Davis Russell, Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454504
DOI https://dx.doi.org/10.2174/1381612033454504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Diastolic Heart Failure and LV Dyssynchrony
Current Pharmaceutical Biotechnology Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Osteopontin as a Potential Therapeutic Target for Ischemic Stroke
Current Drug Delivery ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine Proteomics Analysis Revealed an Altered Left Ventricle Protein Profile in a Mouse Model of Transverse Aortic Constriction
Protein & Peptide Letters Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature
Current Hypertension Reviews The Cytoprotective and Anti-cancer Potential of Bisbenzylisoquinoline Alkaloids from <I>Nelumbo nucifera</I>
Current Topics in Medicinal Chemistry Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Lipid Peroxidation End-Products as Modulators of Catabolic and Inflammatory Responses in Arthritis: A Review
Current Rheumatology Reviews Biomarkers in Atrial Fibrillation and Heart Failure
Current Medicinal Chemistry Retracted: Potential Health Benefits of Broccoli- A Chemico-Biological Overview
Mini-Reviews in Medicinal Chemistry Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews